The latest price of Riflimab in 2025: How much does one dose cost?

Retifanlimab - Zynyz is a monoclonal antibody against programmed death-1 (PD-1) inhibitors, mainly used to treat tumors such as Merkel cell carcinoma (MCC). The drug enhances the body's immune response by inhibiting the PD-1 pathway, allowing the immune system to more effectively identify and attack cancer cells. Riflimab has shown promising efficacy in multiple clinical trials, particularly in the treatment of certain advanced skin cancers and other solid tumors.

Currently, Riflimab is not yet available in the Chinese market, which means that patients cannot obtain the drug through formal channels. In addition, because it is not covered by medical insurance, patients will face a high financial burden when using this drug. In the U.S. market, the price of Riflimab is relatively high, with the price of each box of 500mg/20ml being about RMB 100,000. This price is a significant burden for many patients and limits the accessibility of the drug.

Despite its high price, reflimab has attracted considerable attention for its potential for therapeutic efficacy. It is reported that the safety and effectiveness of the drug have been verified in multiple clinical trials, especially in the treatment of drug-resistant tumors. This makes riflimab an option worth considering when patients are choosing treatment options, especially for those patients who have not responded well to traditional treatments.

In the future, with the further research and accumulation of clinical data on Riflimab, its domestic marketing process may be promoted. If refulimab can be approved and included in medical insurance, it will greatly reduce the financial burden on patients and improve the accessibility of its use. At the same time, this also brings new opportunities for my country's development in the field of tumor immunotherapy.

Reference materials:https://www.drugs.com/mtm/retifanlimab.html